Abstract
Objective
To determine factors associated with failure of same-day trial of void (SDTOV) following
holmium laser enucleation of the prostate (HoLEP).
Background
HoLEP is increasingly utilized for patients with benign prostatic hyperplasia. Advancements
in technology have improved operative efficiency and hemostasis making same-day, catheter-free
discharge possible.
Methods
We conducted a retrospective review on 190 patients undergoing HoLEP from July, 2021
to January, 2022 by a single center. We assessed pre- and intra-operative variables
associated with our primary outcome: failure of same-day catheter removal. Post-operative
complications and outcomes at a ≤7 days and 3-month follow up were examined. Continuous
and categorical variables were analyzed using unpaired t-tests (Mann Whitney) and
chi-square, respectively. Univariate and multivariable logistic regression models
were fitted to examine the associations of failed SDTOV.
Results
Of 190 candidates for a SDTOV, 90% (171/190) were successful. We found no difference
between SDTOV success and failures with regards to age, comorbidities, presence of
pre-operative urinary retention, anesthesia factors, operative time, volume resected,
enucleation time, and morcellation time (all P>0.05). Pre-operatively, 26.3% (50/190) were on antiplatelet and 6.3% (12/190) were
on anticoagulation. While pre-operative antiplatelet therapy was not associated with
SDTOV failure (P=0.78), pre-operative anticoagulation use was (4.7% vs. 21.1%, P=0.021). Patients who continued anticoagulation through surgery had the highest rate
of SDTOV failure (2.3% (4/171) vs. 15.8% (3/19), P=0.023). For those with successful SDTOV, 4.1% (7/171) required catheterization following
discharge. At 3 months, no patient required catheterization.
Conclusion
On the day of surgery, patients eligible for SDTOV successfully voided 90% of the
time. History of preop anticoagulation, whether continued or held, increased SDTOV
failure.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The rising worldwide impact of benign prostatic hyperplasia.BJU Int. 2021; 127: 722-728
- A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update.Eur Urol. 2015; 67: 1066-1096
- Clinical Comparison of Holmium Laser Enucleation of the Prostate and Bipolar Transurethral Enucleation of the Prostate in Patients Under Either Anticoagulation or Antiplatelet Therapy.Eur Urol Focus. 2020; 6: 720-728
- Holmium laser enucleation of the prostate in patients requiring anticoagulation.Curr Urol Rep. 2017; 18: 77
- Comparative study of Holmium Laser Enucleation of the prostate with MOSES enabled pulsed laser modulation.Urology. 2020; 136: 196-201
- Trends and perioperative outcomes across major benign prostatic hyperplasia procedures from the ACS-NSQIP 2011-2015.J Endourol. 2019; 33: 62-68
- Ten-year follow-up results after Holmium Laser Enucleation of the prostate.Eur Urol Focus. 2021; 7: 612-617
- Catheter removal on the same day of Holmium Laser Enucleation of the prostate: Outcomes of a Pilot Study.Urology. 2020; 146: 225-229
- Same day discharge is a successful approach for the majority of patients undergoing Holmium Laser Enucleation of the prostate.Eur Urol Focus. 2021; (S2405-4569(20)30320-5)
- Does MOSES technology enhance the efficiency and outcomes of standard Holmium Laser Enucleation of the prostate? Results of a Systematic Review and Meta-analysis of Comparative Studies.Eur Urol Focus. 2022; (S2405-4569(22)00036-0)
- A visual scale for improving communication when describing gross hematuria.Urology. 2021; 148: 32-36
- Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019.J Urol. 2019; 202: 592-598
- Same-day ischarge following Holmium Laser Enucleation in patients assessed to have large gland prostates (≥175 cc).J Endourol. 2021; 35: 1386-1392
- Expanded criteria same day catheter removal following Holmium Laser Enucleation of the Prostate (HoLEP).J Endourol. 2022; https://doi.org/10.1089/end.2022.0007
Article info
Publication history
Published online: August 09, 2022
Accepted:
July 28,
2022
Received:
March 11,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
